296 related articles for article (PubMed ID: 33432682)
21. Benralizumab Effectiveness in Severe Asthma Is Independent of Previous Biologic Use.
Jackson DJ; Burhan H; Menzies-Gow A; Pfeffer P; Nanzer A; Garcia Gil E; Morris T; Tran TN; Hirsch I; Dube S
J Allergy Clin Immunol Pract; 2022 Jun; 10(6):1534-1544.e4. PubMed ID: 35202871
[TBL] [Abstract][Full Text] [Related]
22. Long-Term Treatment With Anti-Interleukin 5 Antibodies in a Patient with Chronic Eosinophilic Pneumonia.
Shimizu Y; Kurosawa M; Sutoh Y; Sutoh E
J Investig Allergol Clin Immunol; 2020 Apr; 30(2):154-155. PubMed ID: 31778113
[No Abstract] [Full Text] [Related]
23. In severe eosinophilic asthma controlled with benralizumab, tapering high-dose ICS reduced dose while maintaining control.
Stanbrook MB
Ann Intern Med; 2024 Apr; 177(4):JC43. PubMed ID: 38560905
[TBL] [Abstract][Full Text] [Related]
24. Secondary loss of response to mepolizumab in severe eosinophilic asthma.
Cormier M; Chaboillez S; Lemiere C
J Allergy Clin Immunol Pract; 2020 Feb; 8(2):736-738. PubMed ID: 31421278
[No Abstract] [Full Text] [Related]
25. Eosinophil depletion with benralizumab is associated with attenuated mannitol airway hyperresponsiveness in severe uncontrolled eosinophilic asthma.
Chan R; RuiWen Kuo C; Jabbal S; Lipworth BJ
J Allergy Clin Immunol; 2023 Mar; 151(3):700-705.e10. PubMed ID: 36400178
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study.
Numata T; Miyagawa H; Nishioka S; Okuda K; Utsumi H; Hashimoto M; Minagawa S; Ishikawa T; Hara H; Araya J; Kuwano K
BMC Pulm Med; 2020 Aug; 20(1):207. PubMed ID: 32746787
[TBL] [Abstract][Full Text] [Related]
27. Benralizumab for adolescent patients with severe, eosinophilic asthma: Safety and efficacy after 3 years of treatment.
Busse WW; Bleecker ER; FitzGerald JM; Ferguson GT; Barker P; Brooks L; Olsson RF; Martin UJ; Goldman M;
J Allergy Clin Immunol; 2021 Jul; 148(1):266-271.e2. PubMed ID: 33609624
[TBL] [Abstract][Full Text] [Related]
28. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
Jackson DJ; Humbert M; Hirsch I; Newbold P; Garcia Gil E
Adv Ther; 2020 Feb; 37(2):718-729. PubMed ID: 31836949
[TBL] [Abstract][Full Text] [Related]
29. Mepolizumab in adolescents with severe eosinophilic asthma not eligible for omalizumab: one center's early clinical experience.
Weir E; Paton J
J Asthma; 2020 May; 57(5):521-524. PubMed ID: 30795693
[No Abstract] [Full Text] [Related]
30. Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases.
Sridhar S; Liu H; Pham TH; Damera G; Newbold P
Respir Res; 2019 Jan; 20(1):14. PubMed ID: 30658649
[TBL] [Abstract][Full Text] [Related]
31. Cost effectiveness of benralizumab for severe, uncontrolled oral corticosteroid-dependent asthma in Sweden.
Andersson M; Janson C; Kristensen T; Szende A; Golam S
J Med Econ; 2020 Aug; 23(8):877-884. PubMed ID: 32324093
[No Abstract] [Full Text] [Related]
32. Benralizumab as initial treatment for chronic eosinophilic pneumonia.
Yazawa S; Toyoshima M; Koda K; Suda T
Allergol Int; 2021 Jan; 70(1):140-142. PubMed ID: 32807690
[No Abstract] [Full Text] [Related]
33. Severe eosinophilic asthma with nasal polyposis: A phenotype for improved sinonasal and asthma outcomes with mepolizumab therapy.
Howarth P; Chupp G; Nelsen LM; Bradford ES; Bratton DJ; Smith SG; Albers FC; Brusselle G; Bachert C
J Allergy Clin Immunol; 2020 Jun; 145(6):1713-1715. PubMed ID: 32084443
[No Abstract] [Full Text] [Related]
34. [Anti-IL-5 treatments in severe eosinophilic asthma: real life datas].
Özdel Öztürk B; Bavbek S
Tuberk Toraks; 2020 Jul; 68(2):148-159. PubMed ID: 32755115
[TBL] [Abstract][Full Text] [Related]
35. Biological treatment is approved for severe eosinophilic asthma.
Mayor S
BMJ; 2016 Nov; 355():i6472. PubMed ID: 27908911
[No Abstract] [Full Text] [Related]
36. Assessment of eosinophilic nasal inflammation in patients with severe asthma and nasal polyposis before and after six months of therapy with Benralizumab.
Buonamico E; Dragonieri S; Sciancalepore PI; Carratù P; Carpagnano GE; Resta O; Gelardi M
J Biol Regul Homeost Agents; 2020; 34(6):2353-2357. PubMed ID: 33423452
[No Abstract] [Full Text] [Related]
37. Seasonal variability of exacerbations of severe, uncontrolled eosinophilic asthma and clinical benefits of benralizumab.
DuBuske L; Newbold P; Wu Y; Trudo F
Allergy Asthma Proc; 2018 Sep; 39(5):345-349. PubMed ID: 30077185
[TBL] [Abstract][Full Text] [Related]
38. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.
Pelaia C; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Savino R; Pelaia G
Drug Des Devel Ther; 2017; 11():3137-3144. PubMed ID: 29133975
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of Mepolizumab Extended Interval Dosing for 2 Asthmatic Patients With Chronic Eosinophilic Pneumonia.
Sato H; Miyata Y; Inoue H; Tanaka A; Sagara H
J Investig Allergol Clin Immunol; 2021 Oct; 31(5):459-460. PubMed ID: 33502319
[No Abstract] [Full Text] [Related]
40. Clinical Outcomes and Health-Care Resource Use Associated With Reslizumab Treatment in Adults With Severe Eosinophilic Asthma in Real-World Practice.
Wechsler ME; Peters SP; Hill TD; Ariely R; DePietro MR; Driessen MT; Terasawa EL; Thomason DR; Panettieri RA
Chest; 2021 May; 159(5):1734-1746. PubMed ID: 33333058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]